AUS
NZ
UK
CA
USA
IND
Highlights:
- Control Bionics targets 20% revenue growth and near-term EBITDA positivity.
- Sigma Healthcare led healthcare sector gains with a 186% rise over the year.
- Noxopharm secures manufacturing for its autoimmune diseases trial.
Control Bionics (ASX:CBL), a leader in assistive communication technology, anticipates a minimum of 20% revenue growth for the year, backed by an impressive sales backlog now being processed more efficiently. The company also aims to achieve near-term EBITDA positivity in key markets, with its core technology supporting disabled individuals in communication by converting neural signals into actionable codes for device control.
In the company's latest AGM, Control Bionics addressed the hurdles of the past year, such as a $1 million payment backlog from the National Disability Insurance Scheme. Despite a 5% revenue dip in 2023-24, with a reported $5.3 million, the company remains optimistic about future growth. Control Bionics' cutting-edge Neuronode tech allows communication without relying on traditional devices like keyboards or joysticks, offering transformative solutions for users with conditions like motor neuron disease and cerebral palsy. A highlight of its advancements includes the launch of the autonomous wheelchair, Drone, which empowers users with increased mobility.
Healthcare Sector Shifts
In the broader healthcare sector, Sigma Healthcare (ASX:SIG) outshined its peers with a stellar 186% annual rise, as highlighted in a recent sector analysis. Other notable performers include Paragon Care (ASX:PGC), which posted a 166% increase, and Regis Healthcare (ASX:REG), with gains of 141%. These performances contrast with the ASX200 healthcare index, which dipped by 2.1% in September despite a broader market uptick.
While some companies in the sector faced challenges, like ImpediMed (ASX:IPD), which experienced a 64% annual loss, recent months show signs of recovery, with a 27% rebound. These variations highlight the importance of strong fundamentals and innovation in the healthcare space.
Noxopharm's Progress in Autoimmune Disease Treatment
Noxopharm (ASX:NOX) is set to advance its phase I trial for an innovative autoimmune treatment, focusing on cutaneous lupus erythematosus. The company recently secured a contract manufacturer to produce its proprietary molecule, SOF-SKN, for the upcoming trial. This development is crucial for the first-in-human trial of the molecule, aimed at reducing inflammation directly at its source. The preparation process for this trial is expected to take several months, marking a significant step forward for Noxopharm’s research in this niche area.
With healthcare innovations and advancements from companies like Control Bionics and Noxopharm, the sector continues to show resilience and promise for future growth.
